Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
MWN-AI** Summary
Sutro Biopharma, Inc., a clinical-stage oncology company known for its innovative antibody drug conjugates (ADCs), has announced the pricing of an underwritten public offering totaling approximately $110 million. The company will be offering 7,868,383 shares of common stock at $13.98 per share. This offering is set to close around February 11, 2026, pending customary closing conditions. The offering has attracted participation from both new and existing investors, including prominent firms like BVF Partners L.P. and RA Capital Management, and is being managed by Leerink Partners, TD Cowen, and LifeSci Capital.
Sutro plans to utilize the net proceeds from this offering, alongside its existing financial resources, mainly for general corporate purposes. This may encompass funding ongoing research, clinical development, and manufacturing for its product candidates, as well as bolstering working capital and pursuing complementary business opportunities.
The offering is structured under a registration statement that has been previously filed and verified by the Securities and Exchange Commission (SEC). A detailed prospectus supplement will be made available to potential investors, and individuals interested can contact the noted financial firms or visit the SEC's website for more information.
Sutro Biopharma is making strides in the ADC space with a platform that emphasizes the creation of single- and dual-payload ADCs, aiming to enhance therapeutic effects while minimizing side effects for cancer treatment. The company is focused on addressing significant market needs with its pipeline designed to combat treatment resistance and expand patient options in oncology.
As Sutro positions itself for future growth through this funding round, the emphasis on research and development underlines its commitment to advancing cancer therapies.
MWN-AI** Analysis
Sutro Biopharma’s recent announcement regarding its $110 million underwritten public offering at a price of $13.98 per share is significant for both current investors and potential stakeholders. The offering, which could bolster Sutro’s financial position, highlights the company's commitment to advancing its pipeline of next-generation antibody-drug conjugates (ADCs) aimed at oncology.
From a financial perspective, the successful pricing of 7,868,383 shares indicates strong interest from both new and existing investors, including notable firms like BVF Partners and RA Capital Management. This backing not only underscores confidence in Sutro's innovative ADC platform but also suggests that market participants recognize the potential of its product candidates, particularly in addressing treatment-resistant cancers.
Investors should consider the implications of this offering on Sutro's stock price. Historically, equity offerings can lead to temporary stock price dilution. However, the potential capital infusion is expected to enhance the company’s ability to fund research, clinical trials, and strategic initiatives, which may positively impact long-term growth. Therefore, while short-term fluctuations may be expected, long-term investors might view the offering as a strategic move that could lead to significant advancements in Sutro's portfolio.
Given the innovative nature of Sutro’s dual-payload ADC technology, there remains a sizable market opportunity in the oncology sector with increasing demand for advanced therapeutic options. Clients should maintain a cautious but optimistic outlook, focusing on the upcoming clinical milestones and broader industry trends in oncology, which may eventually drive upsides in stock performance.
In conclusion, investors may want to consider entering positions in Sutro Biopharma, particularly if the share price stabilizes post-offering. Regularly monitoring the company's progress in clinical trials and market developments will also be crucial for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions.
The offering includes participation from new and existing investors, including BVF Partners L.P., Samsara BioCapital, Coastlands Capital, Eventide Asset Management, Perceptive Advisors, RA Capital Management, ADAR1 Capital Management, Affinity Asset Advisors and Acuta Capital Partners.
Leerink Partners, TD Cowen and LifeSci Capital are acting as joint bookrunning managers for the proposed offering.
Sutro intends to use the net proceeds of this offering, together with its existing cash, cash equivalents and marketable securities, primarily for general corporate purposes, which may include funding research, clinical and process development and manufacturing of its product candidates, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to the Company, capital expenditures and other general corporate purposes.
The securities are being offered by Sutro pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to this offering, may also be obtained, when available, from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; or LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at compliance@lifescicapital.com Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Sutro, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements the Company makes regarding the satisfaction of customary closing conditions related to the offering and sale of securities, the Company’s ability to complete the offering, anticipated gross proceeds from the offering and expected use of proceeds; anticipated preclinical and clinical development activities, timing of announcements of clinical results, potential efficacy, safety and benefits of STRO-004, potential insights gained and benefits of the Phase 1 trial design; potential benefits of the Company’s other product candidates and platform, and potential market opportunities for the Company’s product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s expectation of market conditions and the satisfaction of customary closing conditions related to the offering, the Company’s ability to complete the offering and expected use of proceeds, the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, and the Company’s commercial collaborations with third parties and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
FAQ**
How does Sutro Biopharma Inc. STRO plan to utilize the approximately $110.0 million gross proceeds from its recent offering for advancing its oncology product pipeline?
What specific competitive advantages does Sutro Biopharma Inc. STRO's cell-free platform provide in developing antibody-drug conjugates compared to traditional methods?
Can Sutro Biopharma Inc. STRO provide insights into how their dual-payload ADCs aim to overcome treatment resistance in cancer therapies?
What risks and uncertainties might impact Sutro Biopharma Inc. STRO's ability to complete the offering and advance its clinical development activities for its product candidates?
**MWN-AI FAQ is based on asking OpenAI questions about Sutro Biopharma Inc. (NASDAQ: STRO).
NASDAQ: STRO
STRO Trading
-7.58% G/L:
$23.40 Last:
34,767 Volume:
$23.61 Open:
